Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

IPHABullishCorporate Developmentsnews

High materiality7/10

Enrollment complete for IPH4502-101; year-end data to guide dose optimization

Jul 21, 2026, 1:03 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Dedicated Phase 1 data release for IPH4502-101 represents a discrete, price-relevant catalyst; if safety remains favorable and early activity persists, IPHA could re-rate ahead of dose-optimization decisions and potential expansion talks.

AI summary

What happened, with direct paths to the underlying reporting

Innate Pharma reports completion of IPH4502-101 dose-escalation enrollment with 76 patients across France and the US. The safety profile remains favorable and early responses are observed in UC post-enfortumab vedotin, NSCLC, and HNSCC, suggesting multi-tumor potential. A year-end data readout will inform dose optimization and potential expansion plans, providing a near-term catalyst for IPHA.

Enrollment completed in IPH4502-101 dose escalation. 76 patients enrolled.
Favorable safety observed to date with limited hematologic toxicity.
Objective responses seen in heavily pre-treated UC post-EV, NSCLC, HNSCC.
Year-end preliminary data will guide dose optimization and expansion potential.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Enrollment complete for IPH4502-101; year-end data to guide dose optimization

Innate-Sobi deal advances lacutamab toward accelerated approval, unlocking milestone upside